Xhance was evaluated in five trials enrolling >1,500 adults. Optinose announced that the Food and Drug Administration (FDA) has approved Xhance (fluticasone propionate) Nasal Spray for the treatment ...

The usual Xhance (fluticasone propionate) dosage for chronic sinus infection is 186 or 372 micrograms (mcg) twice daily. Dosages may vary depending on your symptoms and other medications. Always use ...

YARDLEY, Pa.--(BUSINESS WIRE)--Optinose, an ENT / Allergy specialty pharmaceutical company, announced today that the U.S. Food & Drug Administration (FDA) approved the Company’s New Drug Application ...

YARDLEY, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the ...

Xhance (fluticasone propionate) is a prescription drug that’s used to treat chronic sinusitis. Xhance comes as a nasal spray. Xhance is used in adults to treat chronic (ongoing) sinusitis (sinus ...

Findings showed treatment with Xhance was associated with a statistically significant improvement on both study endpoints compared with placebo. The Food and Drug Administration (FDA) has approved ...

Xhance (fluticasone propionate) is a brand-name drug that’s prescribed for chronic rhinosinusitis with or without nasal polyps in adults. Xhance comes as a nasal spray that’s typically used twice per ...

Optinose Inc (NASDAQ: OPTN) announced the results of pre-planned analyses from the ReOpen trial program evaluating XHANCE for chronic sinusitis. XHANCE (fluticasone propionate) nasal spray is a ...

Improvement was observed across a broad range of measures including multiple symptoms and both general and disease-specific quality of life YARDLEY, Pa., Sept. 29, 2020 /PRNewswire/ -- Optinose ...

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic rhinosinusitis (CRS) nasal spray Xhance for up to $330 million. Triggering the ...

YARDLEY, Pa., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced peer ...

The cost of Xhance can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Xhance. As with all medications, the ...